Skip to content
Subscriber Only

Cathie Wood’s Genomics Fund Is Down 27% and Outflows Are Growing

  • Investors pull $520 million from ARK Genomic ETF in November
  • ARKG has seen most year-to-date outflows out of all Ark funds

Investors appear to be losing patience with Ark Investment Management’s genomics fund. 

The Ark Genomic Revolution ETF (ticker ARKG) has seen roughly $520 million of outflows in November amid sinking returns. The fund is down 27% year-to-date as investors shun health-care stocks in favor for more cyclical names that perform well during an economic recovery. Even so, the ETF is faring far worse than the broader biotech sector, with the Nasdaq Biotechnology Index up 10.49% this year.